{"id":"prednisone-alone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Increased appetite"},{"rate":null,"effect":"Mood changes (irritability, anxiety)"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Acne"},{"rate":null,"effect":"Fluid retention"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prednisone enters cells and binds to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and proliferation. The drug has broad anti-inflammatory and immunosuppressive effects across multiple cell types.","oneSentence":"Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:29.695Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adrenocortical insufficiency"},{"name":"Rheumatoid arthritis"},{"name":"Systemic lupus erythematosus"},{"name":"Asthma"},{"name":"Chronic obstructive pulmonary disease exacerbations"},{"name":"Allergic reactions"},{"name":"Inflammatory bowel disease"},{"name":"Autoimmune hemolytic anemia"},{"name":"Thrombocytopenia"}]},"trialDetails":[{"nctId":"NCT05593497","phase":"PHASE2","title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-05-31","conditions":"High-Risk Prostate Cancer","enrollment":30},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT06421935","phase":"PHASE1","title":"M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-08-07","conditions":"Advanced Solid Tumor","enrollment":141},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT06353386","phase":"PHASE1, PHASE2","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-20","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":220},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT05917522","phase":"PHASE2","title":"Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Kidney Transplant","enrollment":800},{"nctId":"NCT06388564","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2024-10-11","conditions":"Chronic Graft-versus-host-disease","enrollment":120},{"nctId":"NCT07207954","phase":"PHASE1","title":"Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Lifordi Immunotherapeutics, Inc.","startDate":"2025-10-06","conditions":"Rheumatoid Arthritis","enrollment":176},{"nctId":"NCT02257736","phase":"PHASE3","title":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2014-11-26","conditions":"Prostatic Neoplasms","enrollment":982},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT07287397","phase":"PHASE1, PHASE2","title":"Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS","status":"RECRUITING","sponsor":"Vector Y Therapeutics","startDate":"2025-12-19","conditions":"Amyotrophic Lateral Sclerosis","enrollment":12},{"nctId":"NCT00006721","phase":"PHASE3","title":"S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-03","conditions":"Lymphoma","enrollment":571},{"nctId":"NCT05848011","phase":"PHASE2","title":"A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MacroGenics","startDate":"2023-09-28","conditions":"Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent","enrollment":154},{"nctId":"NCT05811351","phase":"PHASE2","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-06","conditions":"Geographic Atrophy","enrollment":305},{"nctId":"NCT04322357","phase":"PHASE2","title":"Twice Weekly Steroids and Exercise as Therapy for DMD","status":"COMPLETED","sponsor":"University of Florida","startDate":"2020-07-30","conditions":"Duchenne Muscular Dystrophy (DMD)","enrollment":21},{"nctId":"NCT04577833","phase":"PHASE1","title":"A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-11-13","conditions":"Prostatic Neoplasms","enrollment":136},{"nctId":"NCT03419234","phase":"PHASE2","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-04-26","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue","enrollment":223},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT04179864","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","status":"TERMINATED","sponsor":"Epizyme, Inc.","startDate":"2019-11-18","conditions":"Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":102},{"nctId":"NCT07228052","phase":"PHASE4","title":"Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-04","conditions":"Asthma","enrollment":182},{"nctId":"NCT06563323","phase":"PHASE2","title":"Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2025-02-01","conditions":"Pyoderma Gangrenosum, Skin Diseases, Wound Heal","enrollment":17},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT04748042","phase":"PHASE2","title":"Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2021-05-28","conditions":"Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease","enrollment":21},{"nctId":"NCT07245732","phase":"PHASE4","title":"Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-04","conditions":"Rheumatoid Arthritis (RA)","enrollment":220},{"nctId":"NCT04623541","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":195},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07221838","phase":"PHASE4","title":"A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab","status":"NOT_YET_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2026-02-27","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":75},{"nctId":"NCT07005154","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-06-19","conditions":"Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer","enrollment":218},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT06246513","phase":"PHASE3","title":"A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2024-01-15","conditions":"Limb-girdle Muscular Dystrophy","enrollment":17},{"nctId":"NCT01931696","phase":"NA","title":"Clinical Assessment of Acupuncture for the Treatment of Chronic Asthma","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2013-08","conditions":"Asthma","enrollment":200},{"nctId":"NCT05470491","phase":"PHASE1, PHASE2","title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-26","conditions":"HIV, Hematologic Malignancies","enrollment":265},{"nctId":"NCT06860243","phase":"PHASE1","title":"A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Hepatic Impairment, Healthy Participants","enrollment":16},{"nctId":"NCT03725202","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-01-24","conditions":"Giant Cell Arteritis (GCA)","enrollment":429},{"nctId":"NCT07431060","phase":"NA","title":"Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2026-02-13","conditions":"Langerhans Cell Histiocytosis (LCH)","enrollment":120},{"nctId":"NCT01314118","phase":"PHASE2","title":"IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2011-05-04","conditions":"Prostate Cancer, Prostatic Neoplasm","enrollment":131},{"nctId":"NCT03755804","phase":"PHASE2","title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-12-12","conditions":"Hodgkin Lymphoma","enrollment":232},{"nctId":"NCT07426484","phase":"PHASE4","title":"Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-07","conditions":"Cutaneous Squamous Cell Carcinoma, Skin Cancer","enrollment":80},{"nctId":"NCT04876651","phase":"PHASE3","title":"The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only","status":"TERMINATED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","startDate":"2023-08-29","conditions":"Metastatic Prostate Cancer","enrollment":16},{"nctId":"NCT04002947","phase":"PHASE2","title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-05","conditions":"Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL","enrollment":132},{"nctId":"NCT05389423","phase":"PHASE1","title":"Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-27","conditions":"Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma","enrollment":25},{"nctId":"NCT03407144","phase":"PHASE2","title":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-09","conditions":"Hodgkin Lymphoma","enrollment":340},{"nctId":"NCT04745949","phase":"PHASE2","title":"PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-10","conditions":"Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma","enrollment":31},{"nctId":"NCT07418177","phase":"PHASE1, PHASE2","title":"Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-10","conditions":"AMD - Age-Related Macular Degeneration","enrollment":9},{"nctId":"NCT03263650","phase":"PHASE2","title":"Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-03","conditions":"Prostate Cancer Aggressiveness, Prostate Carcinoma","enrollment":96},{"nctId":"NCT06630091","phase":"PHASE2","title":"A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-21","conditions":"Peripheral T Cell Lymphoma","enrollment":30},{"nctId":"NCT06894511","phase":"PHASE2","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-09-11","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":7},{"nctId":"NCT02776436","phase":"PHASE1","title":"Reducing Dexamethasone Around Docetaxel Infusion","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2016-01","conditions":"Breast Cancer, Prostate Cancer","enrollment":46},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT06517511","phase":"PHASE2","title":"Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":42},{"nctId":"NCT07404111","phase":"PHASE1, PHASE2","title":"A Study of VV-14305 for the Treatment of Thyroid Eye Disease","status":"NOT_YET_RECRUITING","sponsor":"Kriya Therapeutics, Inc.","startDate":"2026-02","conditions":"Thyroid Eye Disease (TED)","enrollment":110},{"nctId":"NCT04408625","phase":"PHASE1, PHASE2","title":"Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prevail Therapeutics","startDate":"2020-11-09","conditions":"Frontotemporal Dementia","enrollment":35},{"nctId":"NCT07083830","phase":"PHASE1","title":"ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2026-03-30","conditions":"Kidney Transplant Failure and Rejection, Kidney Transplant; Complications","enrollment":24},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT06868381","phase":"PHASE2","title":"A Trial of Baricitinib in Patients With Cardiac Sarcoidosis","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-04-01","conditions":"Cardiac Sarcoidosis","enrollment":10},{"nctId":"NCT06097364","phase":"PHASE3","title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-11-14","conditions":"Follicular Lymphoma (FL)","enrollment":733},{"nctId":"NCT07258771","phase":"PHASE4","title":"Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2026-01-16","conditions":"Ulcerative Colitis Acute","enrollment":110},{"nctId":"NCT07216820","phase":"NA","title":"Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-01-21","conditions":"Shoulder Surgery, Obesity","enrollment":68},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT06040255","phase":"PHASE4","title":"Focal Cerebral Arteriopathy Steroid Trial","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","startDate":"2023-10-01","conditions":"Pediatric Stroke, Arteriopathy, Arterial Ischemic Stroke","enrollment":80},{"nctId":"NCT07362693","phase":"","title":"A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA","status":"NOT_YET_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2025-12-31","conditions":"ABPA, Biologics, Allergic Bronchopulmonary Aspergillosis (ABPA)","enrollment":50},{"nctId":"NCT06470243","phase":"PHASE3","title":"Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-11-27","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":528},{"nctId":"NCT05668676","phase":"PHASE2, PHASE3","title":"Effect of Short-Term Prednisone Therapy on C-Reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers ( CORTAHF )","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-02-16","conditions":"Acute Heart Failure","enrollment":3},{"nctId":"NCT07307534","phase":"NA","title":"Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-01-20","conditions":"Vitiligo, Halo Nevus","enrollment":60},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT05211336","phase":"PHASE1","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-04-19","conditions":"Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS","enrollment":14},{"nctId":"NCT01995058","phase":"PHASE2","title":"Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC","status":"TERMINATED","sponsor":"Exelixis","startDate":"2014-02","conditions":"Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms","enrollment":54},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT02949284","phase":"PHASE2","title":"Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2017-06-20","conditions":"Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT06001125","phase":"PHASE2","title":"Methotrexate for Immune Related Arthritis or Arthralgias (IMPACT 2.1)","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2024-08-12","conditions":"Arthritis, Arthralgia","enrollment":27},{"nctId":"NCT01208766","phase":"PHASE3","title":"Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2011-01","conditions":"Multiple Myeloma","enrollment":1503},{"nctId":"NCT04604067","phase":"PHASE2","title":"Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2021-06-25","conditions":"Diffuse Large B-cell Lymphoma","enrollment":260},{"nctId":"NCT05468320","phase":"PHASE3","title":"Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-11-21","conditions":"Thrombotic Thrombocytopenic Purpura","enrollment":51},{"nctId":"NCT01695005","phase":"PHASE1","title":"A Study of LY3039478 in Participants With Advanced Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-10","conditions":"Neoplasms, Neoplasm Metastasis, Lymphoma","enrollment":247},{"nctId":"NCT07299292","phase":"PHASE2","title":"Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)","status":"RECRUITING","sponsor":"SMED Clinical Research","startDate":"2025-12-01","conditions":"Prostate Cancer (Diagnosis)","enrollment":60},{"nctId":"NCT02985957","phase":"PHASE2","title":"A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-26","conditions":"Prostate Cancer","enrollment":351},{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT03009981","phase":"PHASE3","title":"A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-03-06","conditions":"Prostate Cancer","enrollment":504},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT04411654","phase":"PHASE1, PHASE2","title":"Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prevail Therapeutics","startDate":"2021-06-29","conditions":"Gaucher Disease, Type 2","enrollment":7},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT07275593","phase":"NA","title":"Dexamethasone Versus Prednisolone in Acute Exacerbation of Childhood Asthma","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2024-11-03","conditions":"Acute Exacerbation of Asthma","enrollment":224},{"nctId":"NCT06186648","phase":"PHASE2","title":"Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome","status":"RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2024-03-21","conditions":"Richter Syndrome","enrollment":40},{"nctId":"NCT04540380","phase":"PHASE1","title":"Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-09-01","conditions":"Renal Failure","enrollment":20},{"nctId":"NCT06765980","phase":"PHASE1, PHASE2","title":"A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Kriya Therapeutics, Inc.","startDate":"2025-05-28","conditions":"Geographic Atrophy Secondary to Age-related Macular Degeneration","enrollment":62},{"nctId":"NCT03007732","phase":"PHASE2","title":"Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT","status":"COMPLETED","sponsor":"David Oh","startDate":"2017-05-17","conditions":"Prostatic Neoplasms","enrollment":23},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT05643638","phase":"PHASE2","title":"A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD","status":"RECRUITING","sponsor":"Cynata Therapeutics Limited","startDate":"2024-03-04","conditions":"Graft Versus Host Disease, Acute","enrollment":60},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT07237269","phase":"PHASE2","title":"Abiraterone/Prednisone + Standard ADT vs Standard ADT for Prostate Cancer Patients With PSMA-Positive Conventional Imaging Negative Pelvic Lymphadenopathy","status":"NOT_YET_RECRUITING","sponsor":"University of Nebraska","startDate":"2026-02-01","conditions":"Prostate Cancer","enrollment":140},{"nctId":"NCT04833907","phase":"PHASE1, PHASE2","title":"rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Myrtelle Inc.","startDate":"2021-04-01","conditions":"Canavan Disease","enrollment":24},{"nctId":"NCT06841705","phase":"PHASE2","title":"Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial","status":"RECRUITING","sponsor":"Shilpa Grover, MD, MPH","startDate":"2025-07-15","conditions":"Immune Checkpoint Inhibitor-Related Colitis","enrollment":80},{"nctId":"NCT03721965","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2019-12-31","conditions":"Acute Graft-versus-host Disease","enrollment":2},{"nctId":"NCT03480646","phase":"PHASE1, PHASE2","title":"ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Constellation Pharmaceuticals","startDate":"2017-11-15","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":175}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":487,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["prednisolone"],"phase":"marketed","status":"active","brandName":"Prednisone alone","genericName":"Prednisone alone","companyName":"Guangdong Provincial People's Hospital","companyId":"guangdong-provincial-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Adrenocortical insufficiency, Rheumatoid arthritis, Systemic lupus erythematosus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}